In Phase 2 trials, the most common side effects were nausea, vomiting, diarrhea, and constipation, consistent with other GLP-1 class drugs
This highlights the importance of seeking the expertise and guidance of medical professionals to determine the most suitable treatment and align it to each patients goals, needs, and preferences
The cells were then washed three times with PBS containing 1% BSA (w/v) followed by 1 h incubation with 1:1,000 anti-mouse Alexa Fluor 488 conjugated secondary antibody (diluted with PBS containing 5% BSA, Invitrogen) at RT in the dark
Additional benefits observed: Substantial reduction in knee osteoarthritis pain (75.8% reduction in pain scores) Improved cardiovascular risk markers (non-HDL cholesterol, triglycerides, blood pressure) Up to 86% of participants with fatty liver disease achieved normal liver fat levels Early research suggests retatrutide may lead to substantial weight loss in clinical trial settings, but long-term safety, tolerability, and real-world outcomes still need more data
Weight management and GLP-1 medication concerns should be evaluated by qualified healthcare professionals
But is this approach a promising tool or a risky shortcut
